Comparative evaluation of early treatment with ceftolozane/tazobactam versus ceftazidime/avibactam for non-COVID-19 patients with pneumonia due to multidrug-resistant Pseudomonas aeruginosa

Article

Author: Watanabe, Alexandre H ; Nathanson, Brian H ; Lodise, Thomas P ; Min, Jae ; Yucel, Emre ; Obi, Engels N

AbstractBackgroundCeftolozane/tazobactam and ceftazidime/avibactam are commonly used in patients with MDR-Pseudomonas aeruginosa (PSA) pneumonia (PNA). This study compared outcomes between non-COVID-19 hospitalized patients with MDR-PSA PNA who received ceftolozane/tazobactam or ceftazidime/avibactam.MethodsThe study included non-COVID-19 adult hospitalized patients with MDR-PSA PNA in the PINC AI Healthcare Database (2016–22) who received ceftolozane/tazobactam or ceftazidime/avibactam within 3 days of index culture for ≥2 days. Outcomes were mortality, recurrent MDR-PSA PNA, discharge destination, post-index culture day length of stay (LOS) and costs (in US dollars, USD), and hospital readmission.ResultsThe final sample included 197 patients (117 ceftolozane/tazobactam, 80 ceftazidime/avibactam). No significant differences were observed in mortality and post-index culture LOS and costs between groups. In the multivariable analyses, patients who received ceftolozane/tazobactam versus ceftazidime/avibactam had lower recurrent MDR-PSA PNA (7.9% versus 18.0%, P = 0.03) and 60 day PNA-related readmissions (11.1% versus 28.5%, P = 0.03) and were more likely to be discharged home (25.8% versus 9.8%, P = 0.03). Compared with ceftazidime/avibactam patients, ceftolozane/tazobactam patients had lower adjusted median total antibiotic costs (5052 USD versus 8099 USD, P = 0.003) and lower adjusted median comparator (ceftolozane/tazobactam or ceftazidime/avibactam) antibiotic costs (3938 USD versus 6441 USD, P = 0.005). In the desirability of outcome ranking (DOOR) analysis, a ceftolozane/tazobactam-treated patient was more likely to have a more favourable outcome than a ceftazidime/avibactam-treated patient [DOOR probability: 59.6% (95% CI: 52.5%–66.8%)].ConclusionsEarly treatment with ceftolozane/tazobactam may offer some clinical and cost benefits over ceftazidime/avibactam in patients with MDR-PSA PNA. Further large-scale studies are necessary to comprehensively understand the outcomes associated with these treatments for MDR-PSA PNA.

01 Apr 2024·Journal of Ethnopharmacology

Zishen Yutai pills restore fertility in premature ovarian failure through regulating arachidonic acid metabolism and the ATK pathway

Article

Author: Huang, Qiuling ; Zhou, Su ; Zhang, Chunbo ; Zhang, Minli ; Li, Yan ; Ning, Na ; Su, Biru ; Dang, Lei ; Dong, Yingying ; Wang, Shixuan

ETHNOPHARMACOLOGICAL RELEVANCEThe Zishen Yutai pills (ZYP), a Chinese medicinal formulation derived from the Qing Dynasty prescription "Shou Tai pills", have been documented to exhibit beneficial effects in clinical observations treating premature ovarian failure (POF). However, the anti-POF effects and its comprehensive systemic mechanism have not yet been clarified.AIM OF THE REVIEWTherapeutic effects and systemic mechanism of ZYP in POF were evaluated.MATERIALS AND METHODSAfter pulverization, sieving, and stirring, ZYP was administered intragastrically to cisplatin-induced POF mice at a dose of 1.95 mg/kg/d for 14 days. The anti-POF effects of ZYP were investigated by assessing the number of ovarian follicles at different developmental stages, as well as measuring serum estradiol (E₂) levels and ovarian-expressed anti-Müllerian hormone (AMH). Reproductive performance and offspring health were evaluated to predict fertility restoration. Furthermore, a combination of proteomic and metabolomic profiling was employed to elucidate the underlying molecular mechanism of ZYP in treating POF. Western blot (WB) analyses and real-time quantitative polymerase chain reaction (RT-qPCR) were conducted to explore the mechanisms through which ZYP exerted its anti-POF effects.RESULTSWe have demonstrated that oral administration of ZYP reversed the reduction in follicles at different developmental stages and stimulated the expressions of serum E₂ and ovarian-expressed AMH in a cisplatin-induced POF model. Additionally, ZYP ameliorated follicle apoptosis in ovaries affected by cisplatin-induced POF. Furthermore, treatment with ZYP restored the quantity and quality of oocytes, as well as enhanced fertility. Our results revealed 62 differentially expressed proteins (DEPs) through proteomic analyses and identified 26 differentially expressed metabolites (DEMs) through metabolomic analyses. Both DEPs and DEMs were highly enriched in the arachidonic acid (AA) metabolism pathway. ZYP treatment effectively upregulated the protein and mRNA expression of critical targets in AA metabolism and the AKT pathway, including CYP17α1, HSD3β1, LHR, STAR, and AKT, in cisplatin-induced POF mice.CONCLUSIONSThese results indicated that ZYP exerted protective effects against POF and restored fertility from cisplatin-induced apoptosis. ZYP could be a satisfying alternative treating POF.

01 Mar 2023·European Journal of Medicinal Chemistry

smProdrugs: A repository of small molecule prodrugs

Article

Author: Kumar, Rakesh ; Kumar, Vivek ; Choudhury, Chinmayee

In modern drug discovery and development, the prodrug approach has become a crucial strategy for enhancing the pharmacokinetic profiles of drugs. A prodrug is a chemical compound, which gets metabolized into a pharmacologically active form (drug) inside the body after its administration. In the current work, we report 'smProdrugs' (http://cheminfolab.in/databases/prodrug/), which is one of the first exclusive databases on small molecule prodrugs. It stores the structures, physicochemical properties and experimental ADMET data manually curated from literature. SmProdrugs lists 626 small molecule prodrugs and their active compounds with the above mentioned experimental data from 1808 research articles and 61 patents have been stored. The information page of each record gives the structures and properties of the prodrug and the active drug side by side which makes it easy for the user to instantly compare them. The structural modifications in the prodrug/active drugs are highlighted in a different colour for easy comparison. Experimental data has been curated from the downloaded PubMed and patent articles and were catalogued in a tabular form with more than 25 fields under sub-sections i) name and structures of the prodrugs and their active compounds, ii) mode of activation of the prodrug and enzyme/biocatalyst involved in the conversion, iii) indications/disease, iv) pharmacological target, v) experimental pharmacokinetic properties such as solubility, absorption, volume of distribution, half-life, clearance etc. and vi) information on the purpose/gain from the prodrug strategies. Considering the ever expanding utility of the prodrug approach smProdrugs will be of great use to the scientific community working on rational design of small molecule prodrugs.

100 Deals associated with Bacampicillin Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D00927	Bacampicillin Hydrochloride	J01CA06	DB01602

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Acute Bronchitis	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	12 Sep 2001
Adnexitis	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	12 Sep 2001
Gonorrhea	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	12 Sep 2001
Hordeolum	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	12 Sep 2001
Intrauterine infection	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	12 Sep 2001
Keratitis	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	12 Sep 2001
Laryngitis	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	12 Sep 2001
Lymphadenitis	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	12 Sep 2001
Lymphangitis	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	12 Sep 2001
Non-complicated skin and skin structure infection	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	12 Sep 2001
Otitis Media	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	12 Sep 2001
Pericoronitis	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	12 Sep 2001
Peritonitis	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	12 Sep 2001
Pharyngitis	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	12 Sep 2001
Pneumonia	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	12 Sep 2001
Scarlet Fever	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	12 Sep 2001
Secondary infection	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	12 Sep 2001
Respiratory Tract Infections	China	Heilongjiang Fuhe Huaxing Pharmaceutical Group Co. Ltd.	01 Jan 1993
Soft Tissue Infections	China	Heilongjiang Fuhe Huaxing Pharmaceutical Group Co. Ltd.	01 Jan 1993
Urinary Tract Infections	China	Heilongjiang Fuhe Huaxing Pharmaceutical Group Co. Ltd.	01 Jan 1993

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis